Pluripotent Stem Cell-Derived Therapies for the Treatment of Solid Tumors

Solid tumors can be refractory to many cytotoxic T cell therapies, such as CAR-T therapy, which can have difficulty infiltrating the tumor microenvironment to exert their cancer-killing function.

Our scientists developed a method for treating solid tumors by engineering pluripotent stem cells to create cell therapies that can promote tumor infiltration of cancer-killing immune cells¹⁶.

Pluripotent Stem Cell-Derived Therapies for the Treatment of Solid Tumors is protected by a pending U.S. patent (with additional patents pending in other countries).

• Target solid tumors using pluripotent stem cellderived myeloid cells
• Administer pluripotent stem cell-derived therapies: intratumorally, intraperitoneally, intravenously, or via nebulizer-mediated inhalation
• Combine with Factor’s Combined mRNA Cell Reprogramming & Gene Editing for streamlined manufacturing

• Combine with Factor’s Gene-Edited Allogeneic Cell Therapies Technology to create “off-the-shelf” therapies